SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as retail investors rally behind the company's global expansion efforts and a massive short interest, which many believe is primed for a potential squeeze. The community is actively tracking Dr. Patrick Soon-Shiong's recent communications, viewing the company's international reach and AI-driven manufacturing as catalysts for future value despite ongoing regulatory volatility.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors react to a recent earnings report that exceeded revenue expectations through high-margin licensing deals, even as community sentiment remains polarized over executive compensation and the company's long-term commercial strategy. The discourse is heavily focused on whether management's push for new equity-based incentives is justified given the stock's historical performance, while active discussions highlight potential breakthroughs in pipeline candidates and the impact of activist pressure on future corporate governance.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending following a strong quarterly earnings report that highlighted significant revenue growth, expanded gross margins, and positive momentum in defense and AI edge-computing sectors. Community discussion is focused on the company's strategic pivot toward ruggedized compute solutions for defense and autonomy, with many investors anticipating long-term re-rating potential fueled by bookings growth and defense contract opportunities.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is experiencing heightened volatility and intense debate among retail traders as the community speculates on potential catalysts like NBA sports rights, Disney-backed integration efforts, and upcoming earnings results. While some investors see significant upside potential tied to profitability targets and institutional interest, others are wary due to the stock's history of post-earnings sell-offs and lingering frustration over dilution and management decisions.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is seeing intense trading activity driven by a strong quarterly earnings beat and upward revisions to data center and AI-related growth forecasts, fueling a significant surge in market optimism. Community sentiment is deeply divided, with bulls pointing to robust demand for server CPUs and AI networking as validation for long-term growth, while bears warn of a potential valuation bubble and are actively debating the sustainability of current momentum after such a sharp rally.

Hut 8 Corp. engages in the development and operation of data centers at scale, supporting AI, high-performance computing (HPC), ASIC compute, and other energy-intensive technology applications. It operates through the following segments: Power, Digital Infrastructure, Compute, and Others. The Power segment manages the origination, development, and management of powered land and energy infrastructure. The Digital Infrastructure refers to the development, ownership, and operation of facilities designed to support next-generation, energy-intensive technology application. The Compute segment deals with operating businesses that deploy and monetize compute assets across next-generation energy-intensive technology. The Others segment offers equipment sales and repairs. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 is currently at the center of investor focus following a massive 15-year, $9.8 billion AI data center lease, which has sparked a strong rerating narrative as the company shifts from a crypto miner to an AI infrastructure leader. While some community members remain skeptical of the transition and the reliance on major hyperscalers, bulls are aggressively highlighting the stock's long-term potential, leading to intense debates over its valuation and recent parabolic price action.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is surging as investors pivot toward its potential as an AI infrastructure and power-centric datacenter play, bolstered by a significant expansion in its partnership with AMD. Community sentiment is highly active, with traders closely monitoring technical resistance levels while debating the long-term strategic transformation from pure Bitcoin mining into a critical AI power provider.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk (SNDK) is experiencing a massive parabolic rally fueled by intense AI-driven demand for memory chips, with the stock recently hitting all-time highs above $1,400. While bulls are celebrating massive gains and pointing to long-term storage shortages, the community is actively debating whether this movement reflects genuine AI-fueled fundamental growth or an unsustainable speculative bubble.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc

Ernexa Therapeutics is seeing heightened activity driven by a new manufacturing collaboration with Cellipont Bioservices intended to advance their ovarian cancer candidate, ERNA-101, into clinical trials. While some investors are optimistic about the potential for a squeeze due to the company's low float and strong institutional presence, others are expressing significant caution regarding the stock's history of dilution and reverse splits.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is driving significant buzz as the company shifts from developmental milestones to real-world commercial viability, highlighted by high-profile flight demonstrations in New York City and a strong institutional backing. While the community remains divided between long-term investors tracking FAA certification progress and skeptics focused on cash burn and technical hurdles, active discussions are fixated on the upcoming earnings call and the potential for the company to solidify its position as the leader in urban air mobility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AI Infrastructure Booms, Biotech Breakthroughs Ignite, And Advanced Materials Race Toward Scale

From billion-dollar AI buildouts to preclinical cancer breakthroughs and other milestones, investors are being forced to reassess where the next wave of outsized returns could emerge. $ERNA, $KBLB, $EVC, $NVDA, $GLW, $AHMA

<ul class="summary-bullets"><li>ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells.</li><li>The new collaboration comes as the company looks forward to clinical trials for the cell therapy.&nbsp;</li><li>ERNA-101 has shown potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth in preclinical studies. &nbsp;</li></ul><blockquote>Shares of Ernexa Therapeutics (ERNA) traded 48% higher on Wednesday afternoon after Cellipont Bioservices announced that it has entered into a collaboration with the company.</blockquote>Cellipont is a cell therapy contract development and manufacturing organization. Its <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/cellipont-bioservices-and-ernexa-therapeutics-enter-cell-therapy-manufacturing-partnership-to-advance-erna-101-toward-clinical-trials-in-ovarian-cancer-302597673.html">partnership</a> with Ernexa will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials.<blockquote>"Cellipont brings deep technical capabilities and a shared sense of urgency to help us translate the promise of ERNA-101 into a clinically viable therapy."&nbsp; -Sanjeev Luther, CEO, Ernexa Therapeutics.</blockquote><h2 class="st-heading-2">About The Cell Therapy</h2>ERNA-101 is designed to activate and regulate the immune system's response to recognize and attack cancer cells. According to Cellipont, it provides a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting, provided it is an allogeneic iMSC therapy using stem cells from a healthy donor rather than the patient themselves.ERNA-101 has shown potential to reprogram immunologically "cold" tumors into "hot" ones, increasing immune cell infiltration and suppressing tumor growth in preclinical studies, the company said. The new collaboration comes as the company looks forward to clinical trials for the cell therapy.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ERNA">ERNA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the stock hitting a new high.<stembedurl>https://stocktwits.com/Roza11/message/634186263</stembedurl>Another, however, sees upcoming dilution.<stembedurl>https://stocktwits.com/Tradebub/message/634144629</stembedurl>ERNA stock is down by 58% this year and by 89% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bridgebio-shares-second-postive-late-stage-study-results-in-a-week-calcium-disorder-drug-trial-yields-positive-results/cLGZvEeR3DT">BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

ERNA Stock Rallies On Collaboration With Contract Manufacturer To Advance Lead Cell Therapy Into Clinical Trials 

The partnership will focus on activities to advance Ernexa’s lead cell therapy called ERNA-101 for the treatment of ovarian cancer into clinical manufacturing and trials. 

Equity

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer

Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer Cellipont Bioservices and Ernexa Therapeutics...

Shares of Ernexa Therapeutics (ERNA) fell 13% on Tuesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/10/3096816/0/en/Ernexa-Therapeutics-Announces-1-for-15-Reverse-Stock-Split.html">announced</a> a reverse stock split to regain compliance with the $1 minimum bid price required for continued listing on Nasdaq.The reverse stock split will be at a ratio of 1-for-15, effective June 12, 2025, at 12:01 a.m. Eastern Time. The company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on June 12.As a result of the reverse stock split, every 15 shares of the company’s common stock issued and outstanding will be automatically reclassified into one new share of common stock.No fractional shares will be issued in connection with the reverse stock split, and no cash or other consideration will be paid in connection with any fractional shares.As of Tuesday, the company had 110.4 million shares of common stock issued and outstanding, which it anticipates will result in approximately 7.4 million shares of common stock issued and outstanding on a split-adjusted basis.Ernexa also stated that it believes the reverse stock split is a key step in strengthening its financial foundation and maintaining access to the capital markets needed to advance its clinical programs.Ernexa is developing innovative stem cell therapies for the treatment of advanced cancer and autoimmune disease.On Stocktwits, retail sentiment around Ernexa improved from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:629/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_10_at_10_35_28_AM_png_969f4ebcc6.webp" alt="ERNA's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 10, 2025 | Source: Stocktwits" width="629" height="57"><figcaption>ERNA's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 10, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/ERNA">ERNA stock</a> is down by about 56% this year and by about 91% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tencent-music-expands-audio-empire-with-over-2-billion-ximalaya-merger/chl7VcFRbzk">Tencent Expands Audio Empire With $2.4B Ximalaya Merger: Retail Turns Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Ernexa Stock Drops On 1-For-15 Reverse Stock Split To Regain Nasdaq Compliance: Retail Sentiment Improves But Stays Bearish

As of Tuesday, the company had 110.4 million shares of common stock issued and outstanding, which it anticipates will result in approximately 7.4 million shares on a split-adjusted basis.

This account has been verified as an official ERNA representative.

Verified Account

Ernexa Therapeutics

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

Stocktwits

Stocktwits Polls

Bulls are rallying behind positive preclinical trial results for an ovarian cancer treatment demonstrating 100% tumor elimination in models.

Traders are closely watching the low float and high cost-to-borrow data, hoping to force a violent move against bearish positions.

Skepticism persists regarding recent reverse splits, with some traders citing potential for future dilution and questioning company management.

ERNA
Ernexa Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Compact View

Poll

Latest ERNA News

ERNAErnexa Therapeutics Inc